We are live on ! Find out more
GNMK

GenMark Diagnostics, Inc
GNMK

Delisted

GNMK was delisted on the 21st of April, 2021.

163 hedge funds and large institutions have $974M invested in GenMark Diagnostics, Inc in 2020 Q3 according to their latest regulatory filings, with 35 funds opening new positions, 52 increasing their positions, 56 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

75% more first-time investments, than exits

New positions opened: 35 | Existing positions closed: 20

10% more funds holding

Funds holding: 148163 (+15)

0% more funds holding in top 10

Funds holding in top 10: 33 (0)

3% less capital invested

Capital invested by funds: $1,000M → $974M (-$25.6M)

7% less repeat investments, than reductions

Existing positions increased: 52 | Existing positions reduced: 56

73% less call options, than puts

Call options by funds: $1.63M | Put options by funds: $6.01M

Holders
163
Holders Change
+15
Holders Change %
+10.14%
% of All Funds
3.29%
Holding in Top 10
3
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.06%
New
35
Increased
52
Reduced
56
Closed
20
Calls
$1.63M
Puts
$6.01M
Net Calls
-$4.38M
Net Calls Change
-$5.96M
Name Holding Trade Value Shares
Change
Change in
Stake
FAM
101
Fred Alger Management
New York
$346K +$372K +24,365 New
State of Wisconsin Investment Board
102
State of Wisconsin Investment Board
Wisconsin
$339K +$365K +23,900 New
BIM
103
Bogle Investment Management
Massachusetts
$311K -$401K -26,227 -54%
WI
104
WrapManager Inc
California
$307K -$35.9K -2,348 -10%
Los Angeles Capital Management
105
Los Angeles Capital Management
California
$306K +$1.38K +90 +0.4%
BCM
106
Bayesian Capital Management
New York
$305K +$329K +21,500 New
MLICM
107
Metropolitan Life Insurance Company (MetLife)
New York
$302K
CAM
108
ClariVest Asset Management
California
$294K -$19.9K -1,300 -6%
Ensign Peak Advisors
109
Ensign Peak Advisors
Utah
$279K +$301K +19,669 New
ASRS
110
Arizona State Retirement System
Arizona
$271K +$76.8K +5,026 +36%
WMSA
111
Weiss Multi-Strategy Advisers
New York
$256K -$30.6K -2,000 -10%
AIM
112
Aigen Investment Management
New York
$255K +$275K +17,970 New
PCP
113
Proficio Capital Partners
Massachusetts
$231K
TC
114
TwinBeech Capital
New York
$229K +$246K +16,129 New
BNP Paribas Financial Markets
115
BNP Paribas Financial Markets
France
$229K -$1.11M -72,443 -82%
DCM
116
Dupont Capital Management
Delaware
$224K -$16.1K -1,055 -6%
HF
117
HRT Financial
New York
$219K +$236K +15,437 New
Legal & General Group
118
Legal & General Group
United Kingdom
$211K -$42.9K -2,810 -16%
ONB
119
Old National Bancorp
Indiana
$193K -$99.9K -6,536 -33%
AG
120
Algert Global
California
$191K -$87.1K -5,700 -30%
PP
121
Paloma Partners
Connecticut
$187K +$201K +13,130 New
HC
122
Henshaw Capital
Massachusetts
$179K +$193K +12,627 New
Stifel Financial
123
Stifel Financial
Missouri
$169K -$71.5K -4,681 -28%
Bank of Montreal
124
Bank of Montreal
Ontario, Canada
$166K -$9.35K -612 -5%
SPC
125
Sigma Planning Corp
Michigan
$163K +$175K +11,457 New

GNMK Hedge Fund Activity: Q3 2020 in Review

163 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in GenMark Diagnostics, Inc (GNMK) for Q3 2020, worth a combined $974M — down 2.6% from $1,000M a quarter earlier.

Buyers outnumbered sellers: 35 funds opened new GNMK positions and 20 closed out — a net gain of 15 holders — while 52 added to existing stakes and 56 trimmed.

The largest buyer was Macquarie Group, adding an estimated $20.9M. The largest seller was Consonance Capital Management, cutting an estimated $24.4M.

  • 163 institutional investors held GenMark Diagnostics, Inc (GNMK) as of Q3 2020, up from 148 in Q2 2020.
  • Funds reported $974M of GenMark Diagnostics, Inc stock for Q3 2020, down 2.6% quarter-over-quarter.
  • 35 funds opened new GenMark Diagnostics, Inc positions in Q3 2020 and 20 closed out, a net change of +15 holders.
  • The largest GenMark Diagnostics, Inc buyer in Q3 2020 was Macquarie Group, an estimated $20.9M added.
  • The largest GenMark Diagnostics, Inc seller in Q3 2020 was Consonance Capital Management, an estimated $24.4M sold.

Based on aggregated 13F filings for Q3 2020.